Stay updated on Pembrolizumab+BL-8040 in Metastatic Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+BL-8040 in Metastatic Pancreatic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab+BL-8040 in Metastatic Pancreatic Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe webpage has been updated to reflect a new version of a clinical trial study on pancreatic cancer, including the addition of collaborators and a revision number, while significant details about the trial's objectives and treatment methods have been removed.SummaryDifference57%
- Check38 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 19, 2025.SummaryDifference0.4%
- Check46 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check82 days agoChange DetectedThe webpage has been updated with new results reporting dates and additional details regarding the assessment of treatment outcomes, including the overall response rate and T-cell infiltration metrics. Notably, the previous objective response rate based on RECIST 1.1 has been removed.SummaryDifference10%
- Check96 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Pembrolizumab+BL-8040 in Metastatic Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+BL-8040 in Metastatic Pancreatic Cancer Clinical Trial page.